MacuCLEAR, Inc. And Mystic Successfully Complete Phase Ib Clinical Trial For Macular Degeneration – Medial News Today

MacuCLEAR, Inc. (“MacuCLEAR”) and Mystic Pharmaceuticals, Inc., (“Mystic”) announced preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). The preliminary results indicated that MacuCLEAR’s MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina. Mystic’s VersiDoser™ ophthalmic delivery system was used by trial participants to self-administer MC-1101 to the front of the eye during the trial. The study included Proof Of Concept (“POC”) indicators. A key finding of the study was the […]

2017-05-23T18:33:43+00:00 October 11, 2009|Categories: In the News|0 Comments

Seeing the Future – Texas Aggie Magazine

There’s a disease that leads to blindness. Like most debilitating illnesses of the eye, its progression is defined as gradual, choosing to take sight slightly. One day you can see, and the next—there are shadows, fuzziness, spots. Dark. What would it be like to lose sight? An Aggie-owned company is changing the question: What would it look like to not?

Read the Full Article

2017-05-23T18:33:43+00:00 July 9, 2009|Categories: In the News|0 Comments

MacuCLEAR, Inc. View February 2009

Welcome to MacuCLEAR’s first View Company update for 2009!

This new year has already started off with several positive developments that are detailed in this issue. We are proud of our progress. We greatly appreciate our many stakeholders who are helping us achieve our goal of bringing a treatment for Dry Age Related Macular Degeneration to the millions who suffer from this terrible disease. We are highly motivated to do our best because of the many emails and letters we get from individuals who have found us and want to participate in our clinical development and hope for anything that will […]

2017-05-23T18:33:43+00:00 February 6, 2009|Categories: In the News|0 Comments

Chiou, MacuClear Receive $1.7 Million in Funding – Texas A&M Health Sciences Center College of Medicine

COLLEGE STATION, Texas (May 1, 2007) – George C.Y. Chiou, Ph.D., professor of Neuroscience and Experimental Therapeutics at the Texas A&M Health Science Center College of Medicine, was recently awarded $1.7 million to support MacuClear, the company he founded last year. MacuClear, born from Dr. Chiou’s extensive research into therapeutic drugs for age-related macular degeneration (AMD), is the first start-up company to receive support from the Texas A&M University System and the College of Medicine.

Read the Full Article

2017-05-23T18:33:43+00:00 May 1, 2007|Categories: In the News|0 Comments